302 related articles for article (PubMed ID: 21487112)
1. New markers for minimal residual disease detection in acute lymphoblastic leukemia.
Coustan-Smith E; Song G; Clark C; Key L; Liu P; Mehrpooya M; Stow P; Su X; Shurtleff S; Pui CH; Downing JR; Campana D
Blood; 2011 Jun; 117(23):6267-76. PubMed ID: 21487112
[TBL] [Abstract][Full Text] [Related]
2. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
5. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
Campana D
Curr Opin Hematol; 2012 Jul; 19(4):313-8. PubMed ID: 22525580
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
van Dongen JJ; van der Velden VH; Brüggemann M; Orfao A
Blood; 2015 Jun; 125(26):3996-4009. PubMed ID: 25999452
[TBL] [Abstract][Full Text] [Related]
8. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
9. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
[TBL] [Abstract][Full Text] [Related]
10. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Zhang J; Ding L; Holmfeldt L; Wu G; Heatley SL; Payne-Turner D; Easton J; Chen X; Wang J; Rusch M; Lu C; Chen SC; Wei L; Collins-Underwood JR; Ma J; Roberts KG; Pounds SB; Ulyanov A; Becksfort J; Gupta P; Huether R; Kriwacki RW; Parker M; McGoldrick DJ; Zhao D; Alford D; Espy S; Bobba KC; Song G; Pei D; Cheng C; Roberts S; Barbato MI; Campana D; Coustan-Smith E; Shurtleff SA; Raimondi SC; Kleppe M; Cools J; Shimano KA; Hermiston ML; Doulatov S; Eppert K; Laurenti E; Notta F; Dick JE; Basso G; Hunger SP; Loh ML; Devidas M; Wood B; Winter S; Dunsmore KP; Fulton RS; Fulton LL; Hong X; Harris CC; Dooling DJ; Ochoa K; Johnson KJ; Obenauer JC; Evans WE; Pui CH; Naeve CW; Ley TJ; Mardis ER; Wilson RK; Downing JR; Mullighan CG
Nature; 2012 Jan; 481(7380):157-63. PubMed ID: 22237106
[TBL] [Abstract][Full Text] [Related]
11. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
Faham M; Zheng J; Moorhead M; Carlton VE; Stow P; Coustan-Smith E; Pui CH; Campana D
Blood; 2012 Dec; 120(26):5173-80. PubMed ID: 23074282
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
13. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
[TBL] [Abstract][Full Text] [Related]
14. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
Theunissen P; Mejstrikova E; Sedek L; van der Sluijs-Gelling AJ; Gaipa G; Bartels M; Sobral da Costa E; Kotrová M; Novakova M; Sonneveld E; Buracchi C; Bonaccorso P; Oliveira E; Te Marvelde JG; Szczepanski T; Lhermitte L; Hrusak O; Lecrevisse Q; Grigore GE; Froňková E; Trka J; Brüggemann M; Orfao A; van Dongen JJ; van der Velden VH;
Blood; 2017 Jan; 129(3):347-357. PubMed ID: 27903527
[TBL] [Abstract][Full Text] [Related]
15. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Swerdlow SH; Campo E; Pileri SA; Harris NL; Stein H; Siebert R; Advani R; Ghielmini M; Salles GA; Zelenetz AD; Jaffe ES
Blood; 2016 May; 127(20):2375-90. PubMed ID: 26980727
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
17. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Raetz EA; Cairo MS; Borowitz MJ; Lu X; Devidas M; Reid JM; Goldenberg DM; Wegener WA; Zeng H; Whitlock JA; Adamson PC; Hunger SP; Carroll WL
Pediatr Blood Cancer; 2015 Jul; 62(7):1171-5. PubMed ID: 25732247
[TBL] [Abstract][Full Text] [Related]
18. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Beldjord K; Chevret S; Asnafi V; Huguet F; Boulland ML; Leguay T; Thomas X; Cayuela JM; Grardel N; Chalandon Y; Boissel N; Schaefer B; Delabesse E; Cavé H; Chevallier P; Buzyn A; Fest T; Reman O; Vernant JP; Lhéritier V; Béné MC; Lafage M; Macintyre E; Ifrah N; Dombret H;
Blood; 2014 Jun; 123(24):3739-49. PubMed ID: 24740809
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
20. Evaluating New Markers for Minimal Residual Disease Analysis by Flow Cytometry in Precursor B Lymphoblastic Leukemia.
Jain S; Mehta A; Kapoor G; Bhurani D; Jain S; Agrawal N; Ahmed R; Kumar D
Indian J Hematol Blood Transfus; 2018 Jan; 34(1):48-53. PubMed ID: 29398799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
